§ 3.77 [Amended]

13. In § 3.77(b), by changing the phrase "Bureau of Narcotics and Dangerous Drugs" to read "Drug Enforcement Administration, Department of Justice" each time it appears; and by changing the reference "§ 130.44" to read "§ 310.505."

§ 3.81 [Amended]

14. In § 3.81(d) by changing the reference "§ 130.9 (d) and (e)" to read "§ 314.8(d) and (e)."

§ 3.90 [Amended]

15. In § 3.90(d) by changing the reference "§ 130.9(d)" to read "§ 314.8(d)."

\$3.91 [Amended]

16. In § 3.91:

a. In paragraph (c) (4) (ii) by changing the reference "§ 130.9(d)" to read "§ 314.8(d)."

b. In paragraph (c) (4) (v) by changing the reference "§ 130.4" to read "§ 314.1" each time it appears.

PART 8-COLOR ADDITIVES

§ 8.28 [Amended]

17. In § 8.28(b) by changing in the last sentence the reference "§§ 130.14–130.26 of this chapter" to read "§§ 314.200 through 314.232 of this chapter."

PART 131—INTERPRETIVE STATEMENTS RE WARNINGS ON VETERINARY DRUGS FOR OVER-THE-COUNTER SALE

18. The heading for Part 131 is revised to read as set forth above.

PART 132—REGISTRATION OF PRODUC-ERS OF DRUGS AND LISTING OF DRUGS IN COMMERCIAL DISTRIBU-TION

§ 132.1 [Amended]

19. In § 132.1(d) by changing the reference "§ 130.3" to read "§ 312.1."

§ 132.1 [Amended]

20. In § 132.31(b) by changing the reference "§ 130.3" to read "§ 312.1 of this chapter."

PART 135-NEW ANIMAL DRUGS

§ 135.1 [Amended]

21. In § 135.1(1) by changing the reference "§ 130.38" to read "§ 310.9."

§ 135.37 [Amended]

22. In the introductory text of § 135.37 by changing the reference "§ 130.38" to read "§ 310.9."

PART 144—ANTIBIOTIC DRUGS; EXEMP-TIONS FROM LABELING AND CERTIFI-CATION REQUIREMENTS

§ 144.8 [Amended]

23. In § 144.8 by changing the reference "§ 130.3," each time it appears, to read "§ 312.1."

§ 144.26 [Amended]

24. In § 144.26(b) (18) (1), (22) (1), (32) (1), (35), (39), (42), (44), (45), (49), (50), (54), (56), (59), (60), (61), (62), and (63), by changing the reference "§ 130.4(c) (3)" to read "§ 314.1(c) (3)"; and by changing the reference "§ 130.9" to read "§ 314.8."

PART 146—ANTIBIOTIC DRUGS; PROCE-DURAL AND INTERPRETIVE REGULA-TIONS

§ 146.1 [Amended]

25. In § 146.1(g) (2) by changing the reference "§ 130.12(a) (5)" to read "§ 314.111(a) (5)."

PART 601-LICENSING

§ 601.25 [Amended]

26. In § 601.25(d) (2) by changing the reference "§ 130.12(a) (5) (ii)" to read "§ 314.111(a) (5) (ii)."

The changes being made are nonsubstantive in nature and for this reason notice and public procedure are not prerequisites to this promulgation.

Dated: March 27, 1974.

SAM D. FINE, Associate Commissioner for Compliance.

[FR Doc.74-7384 Filed 3-28-74;8:45 am]

Chapter II—Drug Enforcement Administration; Department of Justice

Part 1301—Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances

Part 1308—Schedules of Controlled Substances

Etorphine Hydrochloride Transfer to Schedule II

A notice dated November 15, 1973, and published in the FEDERAL REGISTER ON November 23, 1973 (38 FR 32262) proposed the transfer of etorphine hydrochloride from Schedule I to Schedule II of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (Pub. L. 91–513). All interested persons were given 30 days after publication to submit their objections, comments, or requests for a hearing.

In response to the said notice, the Administration received two comments and one objection. The Department of Health and Social Services, State of Wisconsin by letter dated December 20, 1973, concurred in the proposed transfer. The Division of Wildlife, Department of Wildlife, State of Colorado, by letter dated December 10, 1973, suggested that the distribution of etorphine hydrochloride should not be limited to licensed veterinarians. The Food and Drug Administration has restricted the use of etorphine hydrochloride and dipren-orphine by or on the order of a licensed veterinarian. The Drug Enforcement Administration shall transmit additional information to the Food and Drug Administration indicating its willingness to permit other qualified persons to use

these substances if the Food and Drug Administration deems it proper and changes the labelling of the substances.

The American Pharmaceutical Association by letter dated December 20, 1973, objected to the restricted distribution of etorphine hydrochloride alleging that the Drug Enforcement Administration does not have the authority to deny any registrant the right to distribute controlled substances in schedules for which he is registered without deciding whether the American Pharmaceutical Association is an interested party with standing to object to the regulation, the Administration clearly has the authority to proscribe regulation, the Administration clearly has the authority to proscribe regulations restricting the distribution of etorphine hydrochloride. Section 871(b) of Title 21 of the United States Code provides that "the Attorney General may promulgate and enforce any rules, regulations, and procedures which he may deem necessary and appropriate for the efficient execution of his functions under this title." Additional authority is found in Sections 301, 307, and 308 of the Controlled Substances Act (21 U.S.C. 827, 823 and 871(b)).

The Administration does acknowledge the necessity for codification of these procedures and amendments to Title 21 of the Code of Federal Regulations are published in this volume of the Federal Register.

Based upon the investigations of the Drug Enforcement Administration and upon the scientific and medical evaluation and recommendation of the Secretary of Health, Education, and Welfare, received pursuant to section 201(b) of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 811 (b)), the Administrator of the Drug Enforcement Administration finds that etorphine hydrochloride:

- (1) Has a high potential for abuse:
- (2) Has a currently accepted medical use in treatment in the United States with severe restrictions; and
- (3) May, if abused, lead to severe psychological or physical dependence.

On July 3, 1973 (38 FR 17717), the Administrator of the Drug Enforcement Administration ordered that § 1303.11(c) of Title 21 of the Code of Federal Regulations be amended by adding a new item, Drotebanol. The amendment to § 1308.11(c) renumbers the items therein to place Drotebanol in alphabetical order with the other controlled substances.

Therefore, under the authority vested in the Attorney General by section 201(a) of the Comprehensive Drug Abuse Prevention and Control Act of 1970 (21 U.S.C. 811(a)), and delegated to the Administrator of the Drug Enforcement Administration by § 0.100 of Title 28 of the Code of Federal Regulations (see 38 FR 18360, July 2, 1973) the Administrator orders that:

a. Section 1301.02(b) of Title 21 of the Code of Federal Regulations be amended by inserting a new paragraph (b) (4) (iv) and renumbering paragraphs (b) (4) (iv)-(xiv) to read:

§ 1301.02 Definitions. (b) * * (4) * * * (iv) Etorphine hydrochloride;(v) Ethylmorphine; (vi) Hydrocodone; (vii) Hydromorphone; (viii) Metopon; (ix) Morphine; (x) Oxycodone; (xi) Oxymorphone; (xii) Thebaine; (xiii) Mixed alkaloids of opium listed in § 1308.12(b) (2) of this chapter; (xiv) Cocaine; and (xv) Ecgonine:

b. Section 1308.11(c) of Title 21 of the Code of Federal Regulations be amended by revising subparagraphs (9)-(23) of paragraph (c) to read:

§ 1308.11 Schedule I.

(c) * * *	
(9) (10)	DrotebanolEtorphine (except hydrochloride	9335
•	sait)	9056
(11)		9200
(12)	Hydromorphinol	9301
(13)	Methyldesorphine	9302
(14)	Methyldihydromorphine	9804
(15)	Morphine methylbromide	9306
(16)	Morphine methylsulfonate	9306
(17)	Morphine-N-Oxide	9307
(18)	Myrophine	9308
(19)	Nicocodeine	9309
(20)	Nicomorphine	9312
(21)	Normorphine	9313
(22)	Pholcodine	9314
(23)	Thebacon	9315

(c) Section 1308.12(b) of Title 21 of the Code of Federal Regulations be amended by revising paragraph (b) (1) to read:

§ 1308.12 Schedule II.

(b) * * * (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium of opiate, excluding naloxone hydrochloride, but including the following:

(ii) Opium extracts	
(iii) Oplum fluid extracts 9 (iv) Powdered opium 9 (v) Granulated opium 9 (vi) Tincture of opium 9 (vii) Apomorphine 9 (viii) Codeine 9 (ix) Ethylmorphine 9 (xi) Hydrocodone 9 (xii) Hydromorphone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	3600
(iv) Powdered opium 9 (v) Granulated opium 9 (vi) Tincture of opium 9 (vii) Apomorphine 9 (viii) Codelne 9 (ix) Ethylmorphine 9 (xi) Hydrocodone 9 (xii) Hydrocodone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xvi) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9610
(v) Granulated opium 9 (vi) Tincture of opium 9 (vii) Apomorphine 9 (viii) Codeine 9 (ix) Ethylmorphine 9 (xi) Hydrocodone 9 (xii) Hydromorphone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xvi) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9620
(vil) Tincture of opium 9 (vil) Apomorphine 9 (vili) Codeine 9 (ix) Ethylmorphine 9 (xi) Hydrocodone 9 (xii) Hydromorphone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9639
(viii) Apomorphine 9 (viii) Codeine 9 (ix) Ethylmorphine 9 (x) Etorphine hydrochloride 9 (xi) Hydrocodone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	3640
(viii) Codelne 9 (ix) Ethylmorphine 9 (x) Etorphine hydrochloride 9 (xi) Hydrocodone 9 (xiii) Hydromorphone 9 (xiiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9630
(ix) Ethylmorphine 9 (x) Etorphine hydrochloride 9 (xi) Hydrocodone 9 (xii) Hydromorphone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9030
(x) Etorphine hydrochloride 9 (xi) Hydrocodone 9 (xii) Hydromorphone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9050
(xi) Hydrocodone 9 (xii) Hydromorphone 8 (xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9190
(xii) Hydromorphone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9059
(xii) Hydromorphone 9 (xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9193
(xiii) Metopon 9 (xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9194
(xiv) Morphine 9 (xv) Oxycodone 9 (xvi) Oxymorphone 9 (xvii) Thebaine 9	9260
(xvi) Oxymorphone 9 (xvii) Thebaine 9	9300
(xvi) Oxymorphone 9 (xvii) Thebaine 9	9143
(xvii) Thebaine 9	9652
	9333

The requirements imposed on the substance controlled by this order are as follows:

1. Registration. Any person who manufactures, distributes, engages in research, imports or exports any of this substance or who proposes to engage in the manufacture, distribution, importa-

tion, or exportation of, or research with, this substance shall obtain a registration to conduct that activity on or before April 19, 1974.

2. Security. This substance must be manufactured, distributed and stored in accordance with §§ 1301.71, 1301.72(a), 1301.73, 1301.74(a), 1301.75, and § 1301.76 of Title 21 of the Code of Federal Regulations. In addition, all registrants desiring to handle etorphine hydrochloride will be required to use a safe or steel cabinet equivalent to a U.S. Government Class V security container after August 1, 1974. In the event that this imposes special hardships, the Drug Enforcement Administration will entertain any justified requests for extensions of time.

3. Labelling and packaging. All labels on commercial containers of, and all labelling of, this substance which is packaged after April 19, 1974 shall comply with the requirements of §§ 1302.03— 1302.05 and 1302.08 of Title 21 of the Code of Federal Regulations. In accordance with § 1302:08 of Title 21 of the Code of Federal Regulations, the Administrator finds that in order to protect the public health and safety early compliance with these requirements is necessitated by the high potential for abuse and the limited medical use of this substance. The shipment of etorphine hydrochloride should be under secure conditions using substantial packaging material with no markings on the outside of the package which would indicate the content. Shipment would be by the most secure means of transport available.

4. Quotas. Quotas for this substance have been established pursuant to section 1303 of Title 21 of the Code of Federal Regulations.

5. Inventory. Registrants possessing this substance will not be required to take an additional inventory.

6. Records. All registrants shall continue to keep records pursuant to §§ 1304.21–1304.27 of Title 21 of the Code of Federal Regulations. In addition, records for this substance shall be maintained separately from all other records on or before April 19, 1974.

7. Reports. All registrants are required to continue filing reports pursuant to Sections 1304.37-1304.41 of Title 21 of the Code of Federal Regulations. In addition, registrants supplying this substance are required to forward copies of the order forms received to the Drug Enforcement Administration on a weekly basis on or before April 19, 1974.

- 8. Order forms. Each distribution of this substance requires the use of an order form pursuant to Part 1305.03 of Title 21 of the Code of Federal Regulations. Order forms for etorphine hydrochloride shall contain this substance alone or with diprenorphine (but shall not contain any other substance) on or after April 19, 1974.
- 9. Prescriptions. The Food and Drug Administration has restricted the use of this substance by or on the order of a licensed veterinarian. Therefore, this substance is not to be obtained by use of a prescription.

10. Importation and exportation. All importation and exportation of any of this substance on or after April 19, 1974 shall be in compliance with Part 1312 of Title 21 of the Code of Federal Regulations.

11. Criminal liability. Any activity with etorphine hydrochloride not authorized by or in violation of the Controlled Substances Act or the Controlled Substances Import and Export Act before April 19, 1974 shall be unlawful. The applicable penalties shall be those of a Schedule I narcotic controlled substance. On April 19, 1974, etorphine hydrochloride for the purposes of criminal liability shall be treated as a Schedule II controlled substance. It should be noted that penalties of Schedule I or II narcotic controlled substances are the same. The only effect of the transfer will be for pleading purposes.

12. Other. In all other respects, this order is effective on April 19, 1974.

Dated: March 25, 1974.

JOHN R. BARTELS, Jr. Administrator Drug Enforcement Administration. [FR Doc.74-7275 Filed 3-28-74;8:45 am]

Title 26—Internal Revenue

CHAPTER I—INTERNAL REVENUE SERVICE, DEPARTMENT OF THE TREASURY

SUBCHAPTER F—PROCEDURE AND ADMINISTRATION

[T.D. 7809]

PART 301-PROCEDURE AND **ADMINISTRATION**

Time for Performance of Acts Where Last Day Falls on a Legal Holiday

By a notice of proposed rulemaking appearing in the FEDERAL REGISTER for Monday, July 16, 1973 (38 FR 18897), an amendment to the regulations on Procedure and Administration (26 CFR Part 301) under section 7503 of the Internal Revenue Code of 1954 was proposed in order to conform such regulations to the changes made by Pub. L. 90–363, 82 Stat. 250, which amended 5 U.S.C. 6103(a), regarding the observance of certain legal holidays on Monday. The amendment of EUSC (103(a)) was affective on Years 5 U.S.C. 6103(a) was effective on January 1, 1971. After consideration of all such relevant matter as was presented by interested persons, certain changes were made, and the proposed amendment of the regulations, subject to the changes indicated below, is adopted by this document.

The amendment to the regulations is designed to conform § 301.7503-1(b) (1) to the present District of Columbia law regarding the date of observance of legal holidays. The District of Columbia now observes Washington's Birthday on the third Monday in February, Memorial Day on the last Monday in May, Veterans' Day on the fourth Monday in October, and Thanksgiving on the fourth Thursday in November. Columbus Day is also considered a legal holiday in the District of Columbia for all calendar years after 1970, and is observed on the